Cannabinoid Encyclopedia

Focused research review

What do we know about CBN safety?

Human CBN safety data are limited and product-specific. Some studies use CBN alone, while others include CBD or other ingredients, so their results do not create one general safety profile.

Updated July 2026 9 research sources Human research included

The short answer

What is the bottom line?

The current evidence does not establish a complete safety profile for CBN. 1 2 3

Small sleep studies can report short-term tolerability in their own participants, while laboratory liver-cell work can identify a possible hazard signal. Neither type of evidence answers every question about dose, long-term use, medicines, pregnancy, driving, or a specific product. 1 2 3

What this means: Read CBN safety source by source. Check the formulation, dose, route, duration, participants, reported adverse events, and whether other cannabinoids or medicines were involved. 1 2 3

How to read this answer: Read CBN safety source by source. Check the formulation, dose, route, duration, participants, reported adverse events, and whether other cannabinoids or medicines were involved. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBN safety.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Short-term tolerability in one CBN sleep study does not establish long-term safety for every CBN product. 1

  2. 2

    CBN with CBD and other combinations cannot answer the isolated-CBN safety question by themselves. 2

  3. 3

    Cell-based liver-hazard signals are important context, but they are not the same as measured injury in people. 3

Choose your question

What CBN safety question are you asking?

Safety depends on the exact product, dose, route, duration, other ingredients, medicines, and person represented in a study.

  1. 01Reader question

    What short-term human data exist?

    See what the small sleep studies did and did not measure.

    Explore the evidence
  2. 02Reader question

    Do combination products answer the CBN-only question?

    No. Other cannabinoids and ingredients change the exposure being studied.

    Explore the evidence
  3. 03Reader question

    What about laboratory safety signals?

    Read cell-based work as a hazard question, not a clinical outcome.

    Explore the evidence

Research areas

What researchers studied about CBN safety

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

Safety, tolerability, sedation, adverse-event, impairment, or formulation-spe...

This part of the literature focuses on Safety, tolerability, sedation, adverse-event, impairment, or formulation-spe.... Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 5

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

7 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

1 source

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

Not prominent

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 1 of 9 research source could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on CBN safety is not one kind of study. This source set includes 4 clinical studies in people, 3 cell or laboratory studies, and 1 narrative or expert review. 3

The recorded populations or models include people or patients (7 sources) and pediatric, adolescent, or developmental context (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns (9 sources). Closely related outcome names can still describe different measurements. 5

The CBN safety source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

clinical study in people

Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial

On this page, this source examines CBN and safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. 1

Study type
clinical study in people
Population or model
people or patients
Outcome focus
safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns
Evidence stage
human research

clinical study in people

A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality

On this page, this source examines CBN and safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. 2

Study type
clinical study in people
Population or model
people or patients
Outcome focus
safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns
Evidence stage
human research

cell or laboratory study

Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids.

On this page, this source examines CBN and safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. 3

Study type
cell or laboratory study
Population or model
people or patients
Outcome focus
safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns
Evidence stage
mechanism-focused research

evidence still limited

Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research.

On this page, this source examines CBN and safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. 4

Outcome focus
safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns
Evidence stage
evidence still limited

cell or laboratory study

Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes.

On this page, this source examines CBN and safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. 5

Study type
cell or laboratory study
Population or model
people or patients
Outcome focus
safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on CBN safety should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 5

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Is CBN safe?

The current evidence is too limited and product-specific to establish general CBN safety. Human study details and laboratory findings answer different questions. 7

Does a short sleep study prove CBN is safe long term?

No. A short study can describe what happened under its own conditions, but it cannot settle long-term safety, interaction, or higher-dose questions. 8

Does CBN interact with medications?

The current CBN source set does not establish a complete interaction profile. Medication questions need product-specific and clinical context. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial clinical study in people; human research PubMed 41698831 DOI 10.1111/jsr.70284
  2. 2
    A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality clinical study in people; human research PubMed 37796540 DOI 10.1037/pha0000682
  3. 3
    Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. cell or laboratory study; mechanism-focused research PubMed 39004335 DOI 10.1016/j.tox.2024.153885
  4. 4
    Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research. evidence still limited PubMed 32053725 DOI 10.1093/annweh/wxaa013
  5. 5
    Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes. cell or laboratory study; evidence still limited PubMed 38924151 DOI 10.1002/jat.4646
  6. 6
    Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. clinical study in people; human research PubMed 39980821 DOI 10.1002/hsr2.70481
  7. 7
    The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. clinical study in people; human research PubMed 37162192 DOI 10.1080/27697061.2023.2203221
  8. 8
    [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences]. narrative or expert review; evidence still limited PubMed 27428345
  9. 9
    Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. cell or laboratory study; evidence still limited PubMed 36228902 DOI 10.1016/j.fct.2022.113458
See all 9 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality clinical study in people; human research / 1 linked research note PubMed 37796540
  2. Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial clinical study in people; human research / 1 linked research note PubMed 41698831
  3. Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. clinical study in people; human research / 1 linked research note PubMed 39980821
  4. Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39004335
  5. The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. clinical study in people; human research / 1 linked research note PubMed 37162192
  6. Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes. cell or laboratory study; evidence still limited / 1 linked research note PubMed 38924151
  7. [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences]. narrative or expert review; evidence still limited / 1 linked research note PubMed 27428345
  8. Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research. evidence still limited / 1 linked research note PubMed 32053725
  9. Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. cell or laboratory study; evidence still limited / 1 linked research note PubMed 36228902